I agree filing of the NDA will be a non event. The catalysts IMHO will be different from what people are thinking. First will be hopefully the denial of CP which should bring some retails investors back. Second would be the acceptance of the NDA. The other potential catalysts are signing of a partner for Europe and may be some kind of down payment dependent on the agreement. Finally the Head and Neck trial; if it is succesfull and it looks like if Neop can potentially get the Sentinel Lymph Node designation then we should be able to get back to the 5s. Unfortunately I do not think the interim look is going to happen till early 2012.